Skip to main content

Table 3 Surgical variables and complications

From: Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer

Variable Value
Patients with radical prostatectomy, n 30
Surgery hindered, n (%)  
  Fibrosis 7 (23.3)
  Vulnerability 1 (3.3)
Surgery duration, min#  
  Median (mean) 195 (208.7)
  Range 140-333
Nerve sparing, n (%)  
  Bilateral 6 (20.0)
  Unilateral 3 (10.0)
  Not possible 21 (70.0)
Intraoperative blood loss, ml  
  Median (mean) 600 (769.2)
  Range 100-2600
No. of transfused blood units, n  
  Median (mean) 0 (0.9)
  Range 0-5
Complications, needing intervention, n (%)§  
  Symptomatic pelvic hematoma 1 (3.3)
  Hydronephrosis 1 (3.3)
  Lymphocele 6 (20.0)
Complications in ≥ 10% of cases, n (%)§  
  Joint pain 3 (10.0)
  Venous/pulmonary thromboembolism 5 (16.7)
Time to catheter removal, days  
  Median (mean) 8 (13.1)
  Range 7-47
Continence, no. of pads, n (%)*  
  0 29 (96.7)
  ≥1 1 (3.3)
Erectile function (n = 26), n (%)*  
  Potent (E 3–4) 4 (15.4)
  Potent with erection aids (E 3–4) 3 (11.5)
  Tumescence (E 1–2) 5 (19.2)
  Impotence (E 0) 14 (53.9)
  1. Abbreviations: #skin incision to skin suture; §within 4 weeks from surgery; *after a median follow up of 48.6 months (range 14.1-87.8).